Home

CureVac N.V. - Ordinary Shares (CVAC)

5.6000
+1.5300 (37.59%)
NASDAQ · Last Trade: Jun 12th, 4:42 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close4.070
Open5.360
Bid5.580
Ask5.620
Day's Range5.350 - 5.720
52 Week Range2.370 - 5.000
Volume22,891,095
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume745,435

Chart

About CureVac N.V. - Ordinary Shares (CVAC)

CureVac N.V. is a biotechnology company focused on developing transformative therapeutics based on its proprietary mRNA technology platform. The company aims to create innovative treatments for various diseases, including cancers and infectious diseases, by harnessing the power of messenger RNA to instruct cells to produce proteins that can elicit a therapeutic effect. CureVac is committed to advancing its vaccine candidates and therapies through rigorous research and clinical trials, striving to deliver next-generation solutions for patients in need of advanced medical treatments. Read More

News & Press Releases

Here are the top movers in Thursday's session.chartmill.com
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 12, 2025
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · June 12, 2025
Nasdaq Moves Higher; Oracle Shares Jump After Upbeat Q4 Resultsbenzinga.com
Via Benzinga · June 12, 2025
Insights Ahead: CureVac's Quarterly Earningsbenzinga.com
Via Benzinga · April 9, 2025
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Dealbenzinga.com
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.
Via Benzinga · June 12, 2025
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · June 12, 2025
There are notable gap-ups and gap-downs in today's session.chartmill.com
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · June 12, 2025
BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatmentstocktwits.com
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares.
Via Stocktwits · June 12, 2025
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.
By Halper Sadeh LLC · Via Business Wire · June 12, 2025
Wondering what's happening in today's pre-market session?chartmill.com
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Via Chartmill · June 12, 2025
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effortbenzinga.com
The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation introduces uncertainty into the nation's defense strategy against H5N1 avian influenza despite positive clinical trial results.
Via Benzinga · May 29, 2025
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Tractionbenzinga.com
CureVac stock surged after reporting Q1 2025 results and a positive pipeline update. The biotech firm narrowed its operating loss, and cash is expected to fund operations through 2028.
Via Benzinga · May 20, 2025
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial Application filed in Europe with decision expected in Q2 2025
Via ACCESS Newswire · May 20, 2025
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendments to specific patent claims
Via ACCESS Newswire · May 15, 2025
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Modestocktwits.com
The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according to FinChat data.
Via Stocktwits · April 10, 2025
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation
Via ACCESS Newswire · April 10, 2025
Earnings Scheduled For April 10, 2025benzinga.com
Via Benzinga · April 10, 2025
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2024 on Thursday, April 10, 2025. The company will host a conference call and webcast on the same day at 3 p.m. CET / 9 a.m. EST.
Via ACCESS Newswire · April 8, 2025
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer
Via ACCESS Newswire · April 7, 2025
Traders are paying attention to the gapping stocks in Friday's session.chartmill.com
Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · March 28, 2025
Top movers in Friday's pre-market sessionchartmill.com
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · March 28, 2025
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Fridaybenzinga.com
Via Benzinga · March 28, 2025
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumpsbenzinga.com
CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025.
Via Benzinga · March 28, 2025
Wondering what's happening in today's after-hours session?chartmill.com
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · March 27, 2025
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form
Via ACCESS Newswire · March 27, 2025